Treatment of Age-Related Lung Abnormalities Using Estrogen and/or Retinoids
Section: For Industry
Category(ies): Viruses, Chronic and Infectious Diseases
Reference #: MADO433806
OTC Contact: Ruchika Nijhara, Ph.D. (Directory Information | Send a Message)
Description
The present invention is directed to methods of treating an age-related loss of lung function. The invention describes use of an estrogen and/or retinoid that specifically bind to Retinoid-Acid- Receptor (RAR).
Applications
- Treating pulmonary diseases such as COPD, asthma, and coronary artery disease
- Treating the age-related loss of alveoli or gas-exchange.
- Diagnostic tool to identify genetic or acquired defect involving RAR function.
Advantages
Stage of Development
Stage of Development: Studies demonstrate that postnatal administration of retinoic acid increases the number of alveoli in rats.
Inventors: Donald Massaro, and Gloria De Carlo Massaro
Relevant Publications
- “Estrogen regulates pulmonary alveolar formation, loss, and regeneration in mice. Massaro et al; Am J Physiol Lung Cell Mol Physiol. (2004) . Dec; 287(6):L1154-9.
- "Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats", Massaro et al, Am. J. Physiol. (1996)., 270, L305-L310
Patent Status
U.S Patent Application # 10/513,136 entitled “Treatment of Age-Related Lung Abnormalities Using Estrogen and/or Retinoids” filed on June 1, 2005.
